Mesoblast Limited reported net revenues of $30.3 million from Ryoncil sales in Q3 FY2026, with gross sales of $35.3 million. The company improved its net operating cash spend to $4.1 million, supported by strong sales in February and March. Mesoblast also achieved patient recruitment targets in a pivotal Phase 3 trial for chronic low back pain and advanced its pipeline with FDA clearance for trials in Duchenne’s muscular dystrophy and adult SR-aGvHD. Additionally, Mesoblast acquired a CAR technology platform to enhance its cell therapy products, positioning itself for future growth in inflammatory and autoimmune diseases.
Mesoblast has reached its goal of treating 300 patients in its pivotal Phase 3 trial of rexlemestrocel-L, a cell therapy for chronic low back pain caused by degenerative disc disease. This trial aims to confirm pain reduction benefits seen in earlier...
Mesoblast has transitioned into a commercial-stage company, anchored by its FDA-approved product Ryoncil, which treats pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). The approval and established manufacturing and reimburseme...
